» Articles » PMID: 16707013

Immunization Coverage and Risk Factors for Failure to Immunize Within the Expanded Programme on Immunization in Kenya After Introduction of New Haemophilus Influenzae Type B and Hepatitis B Virus Antigens

Overview
Publisher Biomed Central
Specialty Public Health
Date 2006 May 19
PMID 16707013
Citations 67
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Kenya introduced a pentavalent vaccine including the DTP, Haemophilus influenzae type b and hepatitis b virus antigens in Nov 2001 and strengthened immunization services. We estimated immunization coverage before and after introduction, timeliness of vaccination and risk factors for failure to immunize in Kilifi district, Kenya.

Methods: In Nov 2002 we performed WHO cluster-sample surveys of >200 children scheduled for vaccination before or after introduction of pentavalent vaccine. In Mar 2004 we conducted a simple random sample (SRS) survey of 204 children aged 9-23 months. Coverage was estimated by inverse Kaplan-Meier survival analysis of vaccine-card and mothers' recall data and corroborated by reviewing administrative records from national and provincial vaccine stores. The contribution to timely immunization of distance from clinic, seasonal rainfall, mother's age, and family size was estimated by a proportional hazards model.

Results: Immunization coverage for three DTP and pentavalent doses was 100% before and 91% after pentavalent vaccine introduction, respectively. By SRS survey, coverage was 88% for three pentavalent doses. The median age at first, second and third vaccine dose was 8, 13 and 18 weeks. Vials dispatched to Kilifi District during 2001-2003 would provide three immunizations for 92% of the birth cohort. Immunization rate ratios were reduced with every kilometre of distance from home to vaccine clinic (HR 0.95, CI 0.91-1.00), rainy seasons (HR 0.73, 95% CI 0.61-0.89) and family size, increasing progressively up to 4 children (HR 0.55, 95% CI 0.41-0.73).

Conclusion: Vaccine coverage was high before and after introduction of pentavalent vaccine, but most doses were given late. Coverage is limited by seasonal factors and family size.

Citing Articles

What predicts complete immunisation among 18-month to 24-month-old children in the urban slum area of Hlaingthayar Township, Yangon Region, Myanmar? A cross-sectional study.

Lynn Z, Han W BMJ Public Health. 2025; 2(2):e001311.

PMID: 40018555 PMC: 11816299. DOI: 10.1136/bmjph-2024-001311.


Determinants of Access to the Pentavalent 3 Vaccine Among Children Aged 0-23 months in Cameroon Based on the Demographic and Health Survey 2018.

Murhabazi Bashombwa A, Tchio-Nighie K, Nanfak A, Buh Nkum C, Nguemnang Nguemnang W, Fri Kami R Pediatric Health Med Ther. 2025; 16:35-45.

PMID: 39963689 PMC: 11830943. DOI: 10.2147/PHMT.S497787.


Assessing the use of geospatial data for immunization program implementation and associated effects on coverage and equity in the Democratic Republic of Congo.

Ngo-Bebe D, Mechael P, Kwilu F, Bukele T, Langwana F, Lobukulu G BMC Public Health. 2025; 25(1):311.

PMID: 39856652 PMC: 11763145. DOI: 10.1186/s12889-025-21578-x.


Interventions for improving coverage of childhood immunisation in low- and middle-income countries.

Oyo-Ita A, Oduwole O, Arikpo D, Effa E, Esu E, Balakrishna Y Cochrane Database Syst Rev. 2023; 12:CD008145.

PMID: 38054505 PMC: 10698843. DOI: 10.1002/14651858.CD008145.pub4.


Machine learning algorithms' application to predict childhood vaccination among children aged 12-23 months in Ethiopia: Evidence 2016 Ethiopian Demographic and Health Survey dataset.

Demsash A, Chereka A, Walle A, Kassie S, Bekele F, Bekana T PLoS One. 2023; 18(10):e0288867.

PMID: 37851705 PMC: 10584162. DOI: 10.1371/journal.pone.0288867.


References
1.
Peltola H . Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 2001; 13(2):302-17. PMC: 100154. DOI: 10.1128/CMR.13.2.302. View

2.
Viviani S, Jack A, Hall A, Maine N, Mendy M, Montesano R . Hepatitis B vaccination in infancy in The Gambia: protection against carriage at 9 years of age. Vaccine. 1999; 17(23-24):2946-50. DOI: 10.1016/s0264-410x(99)00178-4. View

3.
Zuber P, Yameogo K, Yameogo A, Otten Jr M . Use of administrative data to estimate mass vaccination campaign coverage, Burkina Faso, 1999. J Infect Dis. 2003; 187 Suppl 1:S86-90. DOI: 10.1086/368052. View

4.
Murray C, Shengelia B, Gupta N, Moussavi S, Tandon A, Thieren M . Validity of reported vaccination coverage in 45 countries. Lancet. 2003; 362(9389):1022-7. DOI: 10.1016/S0140-6736(03)14411-X. View

5.
Lavanchy D . Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11(2):97-107. DOI: 10.1046/j.1365-2893.2003.00487.x. View